HERTRAZ also known as Trastuzumab is an anticancer drug used for the treatment of HER2-positive breast cancer (around 25% of all breast cancer). Hertraz is also used to treat certain type of stomach cancer. It can be obtained only with prescription.
Manufacturer : Biocon Limited
Strengths available : 150mg & 440mg Vial
Hertraz should be administered as intravenous infusion.
Do not administer as an intravenous push or bolus.
Weekly Schedule: The recommended initial loading dose is 4 mg/kg body weight Hertraz administered as a 90-minute intravenous infusion. Patients should be observed for fever and chills or other infusion-associated symptoms. Interruption of the infusion may help control such symptoms. The infusion may be resumed when symptoms abate.
Subsequent Doses: The recommended weekly dose of Hertraz is 2 mg/kg body weight. If the prior dose was well tolerated, the dose can be administered as a 30-minute infusion.
Patients should be observed for fever and chills or other infusion-associated symptoms.
Most common side effects are Dizziness, fever or chills, headache, muscle aches, nausea or vomiting, skin rash, sore throat, stuffy or runny nose, unusual tiredness or weakness.